Anixa and Moffitt Seek to Improve Potency of CAR T-cell Candidate for Ovarian Cancer

Anixa and Moffitt Seek to Improve Potency of CAR T-cell Candidate for Ovarian Cancer
Anixa Biosciences and Moffitt Cancer Center are seeking to develop a more potent version of their immunotherapy candidate for ovarian cancer, based on chimeric antigen receptor (CAR) T-cell technology, to make it more powerful against ovarian cancer. The optimization efforts may take an additional year, postponing the filing of an Investigational New Drug with the U.S. Food and Drug Administration to late 2020, and the beginning of clinical trials to 2021. "Our technology is the most cutting-edge science and as R&D results mandate, and for the welfare of patients, we must provide the best possible chance of success," Jose Conejo-Garcia, MD, PhD, who invented the product and is a chair of Moffitt's immunology department, said in a press release. "The Anixa and Moffitt teams will strive to get into the clinic as soon as possible with the best possible therapy." CAR T-cell therapy is a novel and rapidly emerging therapy building on the genetic modification of a patient's immune cells to make them able to specifically recognize and attack cancer cells. It involves extracting the immune T-cells (cells with the ability to directly kill malignant cells) from a patient’s blood. Then, in the lab, a viral vector (modified to be harmless) is used to introduce a gene coding for a special receptor, called a chimeric antigen receptor
Subscribe or to access all post and page content.